The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Loss of E-Cadherin Promotes Ovarian Cancer Metastasis via α5-Integrin, which Is a Therapeutic Target
Open accessAbstract
E-cadherin loss is frequently associated with ovarian cancer metastasis. Given that adhesion to the abdominal peritoneum is the first step in ovarian cancer dissemination, we reasoned that down-regulation of E-cadherin would affect expression of cell matrix adhesion receptors. We show here that inhibition of E-cadherin in ovarian cancer cells causes up-regulation of α5-integrin protein expression and transcription. When E-cadherin was blocked, RMUG-S ovarian cancer cells were able to attach and invade more efficiently. This greater efficiency could, in turn, be inhibited both in vitro and in vivo with an α5β1-integrin–blocking antibody. When E-cadherin is silenced, α5-integrin is up-regulated through activation of an epidermal growth factor receptor/FAK/Erk1–mitogen-activated protein kinase–dependent signaling pathway and not through the canonical E-cadherin/β-catenin signaling pathway. In SKOV-3ip1 ovarian cancer xenografts, which express high levels of α5-integrin, i.p. treatment with an α5β1-integrin antibody significantly reduced tumor burden, ascites, and number of metastasis and increased survival by an average of 12 days when compared with IgG treatment (P < 0.0005). α5-Integrin expression was detected by immunohistochemistry in 107 advanced stage ovarian cancers using a tissue microarray annotated with disease-specific patient follow-up. Ten of 107 tissues (9%) had α5-integrin overexpression, and 39% had some level of α5-integrin expression. The median survival for patients with high α5-integrin levels was 26 months versus 35 months for those with low integrin expression (P < 0.05). Taken together, we have identified α5-integrin up-regulation as a molecular mechanism by which E-cadherin loss promotes tumor progression, providing an explanation for how E-cadherin loss increases metastasis. Targeting this integrin could be a promising therapy for a subset of ovarian cancer patients. [Cancer Res 2008;68(7):2329–39]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrins: Versatility, modulation, and signaling in cell adhesion
Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,859
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Molecular requirements for epithelial–mesenchymal transition during tumor progression
Huber, M. A., Kraut, N., & Beug, H. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.08.001 · Cited by 1,821
Cell adhesion and signalling by cadherins and Ig-CAMs in cancer
Cavallaro, U., & Christofori, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1276 · Cited by 1,311
Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology*
Auersperg, N., Wong, A. S. T., Choi, K.-C., Kang, S. K., & Leung, P. C. K. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0422 · Cited by 1,046
Hoschuetzky, H., Aberle, H., & Kemler, R. (1994) · The Journal of cell biology · doi:10.1083/jcb.127.5.1375 · Cited by 711
Kim, S., Bell, K., Mousa, S. A., & Varner, J. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65005-5 · Cited by 635
Let-7 expression defines two differentiation stages of cancer
Shell, S., Park, S.-M., Radjabi, A. R., Schickel, R., Kistner, E. O., Jewell, D. A., Feig, C., Lengyel, E., & Peter, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704372104 · Cited by 458
Self-citationQian, X., Karpova, T., Sheppard, A. M., McNally, J., & Lowy, D. R. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600136 · Cited by 396
Lengyel, E., Prechtel, D., Resau, J. H., Gauger, K., Welk, A., Lindemann, K., Salanti, G., Richter, T., Knudsen, B., Vande Woude, G. F., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.20598 · Cited by 273
Self-citation
Cited by
Exploring the Role of RGD-Recognizing Integrins in Cancer
Nieberler, M., Reuning, U., Reichart, F., Notni, J., Wester, H.-J., Schwaiger, M., Weinmüller, M., Räder, A., Steiger, K., & Kessler, H. (2017) · Cancers · doi:10.3390/cancers9090116 · Cited by 429
Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium
Iwanicki, M. P., Davidowitz, R. A., Ng, M. R., Besser, A., Muranen, T., Merritt, M., Danuser, G., Ince, T., & Brugge, J. S. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-11-0010 · Cited by 303
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Worzfeld, T., Pogge von Strandmann, E., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., & Müller, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00024 · Cited by 288
Lipid rafts: signaling and sorting platforms of cells and their roles in cancer
Staubach, S., & Hanisch, F.-G. (2011) · Expert Review of Proteomics · doi:10.1586/epr.11.2 · Cited by 284
Mitra, A. K., Sawada, K., Tiwari, P., Mui, K., Gwin, K., & Lengyel, E. (2011) · Oncogene · doi:10.1038/onc.2010.532 · Cited by 274
Self-citation
Metadata
- Authors
- Sawada, K., Mitra, A. K., Radjabi, A. R., Bhaskar, V., Kistner, E. O., Tretiakova, M., Jagadeeswaran, S., Montag, A., Becker, A., Kenny, H. A., Peter, M. E., Ramakrishnan, V., Yamada, S. D., & Lengyel, E.
- Venue
- Cancer Research
- Published
- 2008-04-01
- Volume
- 68
- Issue
- 7
- Pages
- 2329-2339
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2150823776
- Cited by
- 356
- References
- 38
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Loss of E-Cadherin Promotes Ovarian Cancer Metastasis via α5-Integrin, which Is a Therapeutic Target. https://app.cochat.ai/papers/10.1158/0008-5472.can-07-5167
- The paper
- Sawada, K., Mitra, A. K., Radjabi, A. R., Bhaskar, V., Kistner, E. O., Tretiakova, M., Jagadeeswaran, S., Montag, A., Becker, A., Kenny, H. A., Peter, M. E., Ramakrishnan, V., Yamada, S. D., & Lengyel, E. (2008). Loss of E-Cadherin Promotes Ovarian Cancer Metastasis via α5-Integrin, which Is a Therapeutic Target. Cancer Research. https://doi.org/10.1158/0008-5472.can-07-5167
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.